• Explore /
  • Poster
  • / Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

Abstract Poster

Authors

null

Giulia Martini

Medical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy

Giulia Martini , Stefania Napolitano , Vincenzo Famiglietti , Filippo G. De Braud , Marinella Terminiello , Carola Borrelli , Pietro Paolo Vitiello , Antonio Avallone , Nicola Normanno , Evaristo Maiello , Alfredo Falcone , Giuseppe Santabarbara , Carmine Pinto , Daniele Santini , Alessandra Di Liello , Daniela Renato , Lucia Esposito , Francesca Marrone , Teresa Troiani , Davide Ciardiello

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT04561336

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3578)

DOI

10.1200/JCO.2021.39.15_suppl.3578

Abstract #

3578

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ramya Thota

First Author: Sheng Li

First Author: Naoki Takahashi

First Author: John H. Strickler